Oman's NPI starts drug plant in Muscat
At a cost of 11 million rial ($28.6 million), Oman's NationalPharmaceutical Industries has begun construction of a pharmaceutical plant in Muscat, according to NPI general manager Arvind Bhalerao, who told Reuters that production should begin early next year. Major investors in the project are Al Yousef International, Suhail Salim Bahwan of the Bahwan Group and Oman's Ministry of Health.
Local production of medicines will reduce the amount of imported pharmaceuticals needed for the country's 47 hospitals and 117 health clinics, according to a Health Ministry spokesman.
NPI is the second company in Oman to build a pharmaceutical plant, Reuters said, noting that in March the Ajay Group said it was planning to build a 10 million rial facility in Salalah.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze